Albany Molecular Research (NASDAQ: AMRI) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, earnings, dividends, profitability, analyst recommendations, valuation and risk.
This is a summary of current recommendations for Albany Molecular Research and Enanta Pharmaceuticals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Albany Molecular Research||0||4||0||0||2.00|
Valuation and Earnings
This table compares Albany Molecular Research and Enanta Pharmaceuticals’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Albany Molecular Research||N/A||N/A||N/A||($1.43)||-15.20|
|Enanta Pharmaceuticals||$102.81 million||10.65||$17.71 million||$0.88||65.07|
Enanta Pharmaceuticals has higher revenue and earnings than Albany Molecular Research. Albany Molecular Research is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
72.1% of Albany Molecular Research shares are owned by institutional investors. Comparatively, 66.8% of Enanta Pharmaceuticals shares are owned by institutional investors. 14.5% of Albany Molecular Research shares are owned by company insiders. Comparatively, 9.3% of Enanta Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
This table compares Albany Molecular Research and Enanta Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Albany Molecular Research||-5.93%||-13.39%||-3.42%|
Volatility & Risk
Albany Molecular Research has a beta of 1.17, indicating that its share price is 17% more volatile than the S&P 500. Comparatively, Enanta Pharmaceuticals has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500.
Enanta Pharmaceuticals beats Albany Molecular Research on 7 of the 11 factors compared between the two stocks.
Albany Molecular Research Company Profile
Albany Molecular Research, Inc. is a contract research and manufacturing company. The Company operates through Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP) and Fine Chemicals (FC) segments. The DDS segment includes activities, such as drug lead discovery, optimization, drug development and small scale commercial manufacturing. The API segment includes pilot to commercial scale manufacturing of active pharmaceutical ingredients and intermediates. The DP segment includes pre-formulation, formulation and process development through commercial scale production of complex liquid-filled and lyophilized sterile injectable products and ophthalmic formulations. The FC segment includes lab to commercial scale synthesis of reagents and diverse compounds. It supplies a range of services and technologies supporting the discovery and development of pharmaceutical products, the manufacturing of API and drug product for new and generic drugs.
Enanta Pharmaceuticals Company Profile
Enanta Pharmaceuticals, Inc. is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV). It has discovered novel protease inhibitors that are members of the direct-acting-antiviral (DAA) inhibitor classes designed for use against the hepatitis C virus (HCV). These protease inhibitors, developed through its collaboration with AbbVie Inc. (AbbVie), include paritaprevir and glecaprevir (ABT-493). Its product candidates also include EDP-305, which is a farnesoid X receptor (FXR) agonist product candidate for NASH and PBC, and EDP-938, which is a clinical candidate for RSV.
Receive News & Ratings for Albany Molecular Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albany Molecular Research and related companies with MarketBeat.com's FREE daily email newsletter.